ArticleAntimicrobial agents and chemotherapy2009
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
Article in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 89 citations in OpenAlex.
- Phylogenetic analyses and antimicrobial resistance profiles of Campylobacter spp. from diarrhoeal patients and chickens in Botswana.PloS one · 2018Trial
- Virulence and Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2026Review
- Comprehensive genomic insights into lineages, virulence, and antibiotic resistance profiles of Campylobacter jejuni entailing a global One Health scenario.Gut pathogens · 2026Article
- Antimicrobial Resistance Profiles of Gram-Negative Bacteria Isolated from Saker Falcons (Antibiotics (Basel, Switzerland) · 2026Article
- Recurrent Campylobacter jejuni bacteraemia with independent acquisition of carbapenem resistance in three ST9611 isolates: a case series in immunocompromised hosts.Gut pathogens · 2026Article
- Antimicrobial Activity of a Synthetic Brevibacillin Analog Against Multidrug-ResistantInternational journal of molecular sciences · 2025Article
- Comparative Genomic Analysis of Livestock-DerivedJournal of microbiology and biotechnology · 2025Article
- The Global Challenge ofTropical medicine and infectious disease · 2025Review
- Genomic analysis and antimicrobial resistance in human- and poultry-derivedFrontiers in microbiology · 2025Article
- Isolation and characterization of novel lytic bacteriophages against (fluoro)quinolone-resistantFrontiers in microbiology · 2025Article
- Genotypic characterization and antimicrobial susceptibility of humanMicrobiology spectrum · 2024Article
- Exploring the Role of the Environment as a Reservoir of Antimicrobial-ResistantMicroorganisms · 2024Article
- Five centuries of genome evolution and multi-host adaptation ofMicrobial genomics · 2024Article
- Insights on the genomic diversity, virulence and resistance profile of a Campylobacter jejuni strain isolated from a hospitalized patient in Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Clinical Outcomes of Patients With Nontyphoidal Salmonella Infections by Isolate Resistance-Foodborne Diseases Active Surveillance Network, 10 US Sites, 2004-2018.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Genomic diversity of Campylobacter jejuni and Campylobacter coli isolated from the Ethiopian dairy supply chain.PloS one · 2024Article
- Virulence factors and antimicrobial resistance profiles ofMicrobiology spectrum · 2023Article
- First report of phenotypic and genotypic (blaVeterinary world · 2023Article
- Recurrent Campylobacter jejuni Infections withMicrobiology spectrum · 2023Article
- Antimicrobial resistance inMicrobial genomics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fifty-two percent of 1,288 poultry isolates of campylobacters were ampicillin resistant, and resistance was more common among Campylobacter coli isolates (67.4%) than among Campylobacter jejuni isolates (47.5%). Production of beta-lactamase was typically associated with resistance to ampicillin, amoxicillin (amoxicilline), penicillin, and ticarcillin. Regardless of beta-lactamase production, all isolates were resistant to piperacillin (MICs >or= 256 microg/ml), and most were resistant to carbenicillin, cloxacillin, and cephalosporins. Of all ampicillin-resistant campylobacters tested, 91% (347/380) carried the bla(OXA-61) gene, and 77% (136/175) of those tested with nitrocefin produced a beta-lactamase, presumably OXA-61. The isoelectric point (pI) of OXA-61 was 8.7, and the molecular mass was 31.0 kDa. Insertional inactivation of bla(OXA-61) in C. jejuni NCTC 11168 and two ampicillin-resistant isolates resulted in increased susceptibility to ampicillin, co-amoxiclav (amoxicillin and clavulanic acid), penicillin, carbenicillin, oxacillin, and piperacillin, but the effects on MICs of cephalosporins and imipenem were negligible. Some C. jejuni isolates that lacked bla(OXA-61) produced a beta-lactamase, CjBla2, with a pI of 9.2 and molecular mass of 32.4 kDa. Mass spectrometry confirmed that the most prevalent beta-lactamase was the product of bla(OXA-61), but CjBla2 was not identified. OXA-61 is prevalent among Campylobacter spp. of veterinary origin and is similar to the beta-lactamase previously reported in human isolates. Production of OXA-61 was associated with resistance to penams but not cephalosporins. Co-amoxiclav remained active against all isolates tested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.